Rephonic
Artwork for On The Pen GLP-1 News
Glp-1 Medications
Eli Lilly
Glp-1
Zepbound
Obesity
Novo Nordisk
Mounjaro
Wegovy
FDA
Terzepatide
Diabetes
Obesity Medicine
Retatrutide
Ozempic
Semaglutide
Weight Loss
Cagrisema
Medicare
Obesity Treatment
Type 2 Diabetes

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

PublishesTwice weeklyEpisodes191Founded2 years ago
Number of ListenersCategories
Health & FitnessMedicine

Listen to this Podcast

Artwork for On The Pen GLP-1 News

Latest Episodes

This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safety and patient safety, especially concerning presc... more

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of the numbers that were so incredible to hear. This... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Recent Guests

Jen Kinnoosh
Expert following GLP-1 studies and obesity medications; active member of On The Pen community
Episode: The Next Two Weeks in GLP1 Are Huge, Here's Why
Kyler Ockey
Chief Product Officer at Shed
Shed
Episode: He Took Retatrutide 40mg and Proved a Point
Sabina Hemmi
Expert commentator from GLP-Winner
GLP-Winner
Episode: BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Spencer Nadolsky
Board-certified obesity medicine doctor
Vineyard (clinic)
Episode: Ozempic Personality With Dr Spencer Nadolsky
Dr. Ian Ellis
Physician and founder of VoaFit, ER physician
VoaFit
Episode: Zepbound Dosing: What Your Doctor Didn't Explain
Shantanu Gaur
CEO of Allurion, a company pioneering non-surgical obesity treatments
Allurion
Episode: GLP-1 PLUS Gastric Balloon for added Weight Loss!
Sabina Hemme
Founder of GLP Winter, a company that helps patients compare access options for GLP-1 medications
GLP Winter
Episode: GLP-1 Compound Legislation: States are the Next Battlefield w/ Sabina Hemme
Max Bayer
Pharma reporter at Endpoints News, focuses on drug pricing and pharmaceutical policy.
Endpoints News
Episode: TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!
Harith Rajagopalan
Doctor and CEO of Fractal Health
Fractal Health
Episode: Retatrutide News That Could Change Everything for GLP-1 Compounds

Host

Dave Knapp
Host of On The Pen GLP-1 News; frequent presenter on GLP-1 market and policy topics; links with obesity medicine and access discussions.

Reviews

4.9 out of 5 stars from 585 ratings
  • Health news

    I truly enjoy Dave bringing us the latest and greatest news when it comes to health and obesity news. He is so informative in this space.

    Apple Podcasts
    5
    Letiwilson
    United Statesa month ago
  • Intelligent, current information

    Always relevant and timely. As a clinician, I appreciate Dave’s careful framing of the news he shares.

    Apple Podcasts
    5
    memesusan
    United States2 months ago
  • Always Important Info Here!

    I’ve listened to Dave’s On The Pen YouTube and podcast for years now and consider it a regular must listen for the ever changing world of all things GLP-1 type medications. He shares cutting edge science, breaking news and their real world implications, profound interviews as well as his personal experiences with GLP1 use. Hands down the best, most solid information out there in this sphere!

    Apple Podcasts
    5
    Sunshiny4
    United States2 months ago
  • Up to date news!

    Thank you Dave, for giving us the most up to date news in this space. How can we band together to rally for more affordable access? The middle class is still getting killed with drug costs and we need our current administration to see that?

    Apple Podcasts
    5
    JFair2
    United States2 months ago
  • Definitely recommend!

    Edit on 3.17.2026

    Yes I still follow Dave, he’s been keeping us updated on all the new peptides and all the new trials, he is fantastic! Nobody else has this important information and fights for advocacy, while keeping it real like Dave! Thank you for breaking down barriers to this life saving medication, and being honest with us! Grateful!

    I found Dave’s pod through his YouTube channel over the summer, and yes I’ve kept up with the ongoing craziness because of Dave. He shares lots of really im... more

    Apple Podcasts
    5
    TourGirl555
    United States2 months ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Dave Knapp is consistently seen as knowledgeable and trustworthy in GLP-1 news.
The show is praised for staying up-to-date and advocating for patient access during regulatory shifts.
Guests often highlight the host's ability to connect clinical relevance with market dynamics.
Listeners value the data-driven approach and clear explanations of complex policy.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

The Next Two Weeks in GLP1 Are Huge, Here's Why
Q: What are your expectations for the Transcend study in diabetics, and how could the results reshape weight-loss expectations across populations?
Transcend has shown substantial weight loss in diabetics with the 40-week data, and the curves without a plateau suggest continued potential; if the results hold, diabetics could see significantly higher weight loss than non-diabetics, which would drive more disease-specific expectations and possibly new combination strategies.
The Next Two Weeks in GLP1 Are Huge, Here's Why
Q: How might real-world titration and dose changes influence how physicians prescribe these meds compared with trial protocols?
Clinicians will likely adopt more individualized titration strategies, adjusting doses based on tolerability and response, rather than sticking to fixed high-dose regimens; this could mean earlier dose reductions or stepwise adjustments to maintain weight loss while minimizing side effects.
The Next Two Weeks in GLP1 Are Huge, Here's Why
Q: Jen, tell us about what data we should expect to see at the European Obesity Congress and ADA sessions regarding maintenance studies like Sermount Maintain and Attain Maintain.
We should see top-line and, potentially, more granular data including categorical outcomes by BMI, maintenance dose comparisons (max tolerated dose vs. 5 mg vs. placebo), and safety signals over extended periods to understand durability and tolerability across patient subgroups.
BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Q: What does the practical transition look like for telehealth companies now that these suppliers are stepping back?
Telehealth companies will need to quickly identify which compounding partners remain available, understand batch sizes and production timelines, and communicate expected delays to patients. The shift may cause initial weeks-long delays as new suppliers-scale, followed by gradual stabilization as 503As ramp up and solidify supply chains.
BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Q: Sabina, what is the immediate impact of losing ProRx and BPI?
The immediate impact is significant delays in the compounded GLP-1 supply, as large players exiting the market reduce overall capacity. While 503As can ramp up, the transition to new suppliers takes time and can create bottlenecks, with distributors potentially continuing to ship through remaining networks before shortages materialize fully.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About On The Pen GLP-1 News

What is On The Pen GLP-1 News about and what kind of topics does it cover?

This show provides up-to-date, data-driven coverage of GLP-1 therapies, obesity medicine, FDA actions, drug access, and the evolving market landscape. Episodes mix regulatory shifts, pricing, and access with practical takeaways for clinicians, patients, and providers, often featuring medical experts, policy analysts, and industry commentators. A consistent strength is translating complex trial data and policy changes into actionable insights for real-world decision-making, with a clear focus on patient access and the business of obesity medicines. The format tends to blend quick news updates, in-depth market analysis, and expert perspectives, making it valuable for professionals tracking GLP-1 developments, sponsors seeking brand and though... more

Where can I find podcast stats for On The Pen GLP-1 News?

Rephonic provides a wide range of podcast stats for On The Pen GLP-1 News. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to On The Pen GLP-1 News and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does On The Pen GLP-1 News get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for On The Pen GLP-1 News, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for On The Pen GLP-1 News?

Rephonic provides comprehensive predictive audience data for On The Pen GLP-1 News, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does On The Pen GLP-1 News have?

To see how many followers or subscribers On The Pen GLP-1 News has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to On The Pen GLP-1 News?

These podcasts share a similar audience with On The Pen GLP-1 News:

1. The Plus SideZ: A GLP-1 Guide to Metabolic Health
2. The Obesity Guide with Matthea Rentea MD
3. GLP-1 Hub: Support, Community, and Weight Loss
4. The Holistic GLP-1 Podcast with Elizabeth McGann
5. Your GLP-1 Bestie

How many episodes of On The Pen GLP-1 News are there?

On The Pen GLP-1 News launched 2 years ago and published 191 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact On The Pen GLP-1 News?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for On The Pen GLP-1 News?

Rephonic pulls ratings and reviews for On The Pen GLP-1 News from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for On The Pen GLP-1 News?

Rephonic provides full transcripts for episodes of On The Pen GLP-1 News. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on On The Pen GLP-1 News?

Recent guests on On The Pen GLP-1 News include:

1. Jen Kinnoosh
2. Kyler Ockey
3. Sabina Hemmi
4. Spencer Nadolsky
5. Dr. Ian Ellis
6. Shantanu Gaur
7. Sabina Hemme
8. Max Bayer

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days